GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, …
GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58;
GARDASIL 9 HOME - gardasil9-cdsi - merckvaccines.com
GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerou...
FDA Approves Merck's HPV Vaccine, GARDASIL®9, to Prevent …
Dec 11, 2014 · GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58.
GARDASIL 9 | FDA - U.S. Food and Drug Administration
Mar 15, 2024 · Product approval information for Human Papillomavirus 9-valent Vaccine, Recombinant also known as Gardasil 9.
FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain …
Jun 12, 2020 · GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Now Approved for the Prevention of HPV-Related Cervical, Vaginal, Vulvar, Anal, Oropharyngeal and Other Head and Neck Cancers.
Merck’s 9-Valent HPV Vaccine, GARDASIL®9, Recommended by …
Feb 26, 2015 · GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) added to CDC’s Vaccines for Children program. During today’s meeting, the ACIP also voted to include GARDASIL 9 in the CDC’s Vaccines for Children (VFC) program for both boys and girls. Since 1994, the VFC program has provided vaccines to children through
Gardasil | FDA - U.S. Food and Drug Administration
Proper Name: Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant Tradename: Gardasil Manufacturer: Merck & Co., Inc. Indications: Prevention of vulvar and vaginal cancer
Vaccination with GARDASIL may not result in protection in all vaccine recipients. GARDASIL has not been demonstrated to prevent HPV-related CIN 2/3 or worse in women older than 26 years...
Dosage and Administration for GARDASIL 9
GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58;
HPV Vaccine Administration | CDC - Centers for Disease Control …
HPV vaccination is administered as: A three-dose series (0, 1-2, 6 months) for persons who initiate vaccination at ages 15 through 45 years, and for immunocompromised persons.